Rimantadine

Summary

Rimantadine (CHEMBL959) is an approved small molecule (ATC J05AC02); indicated across 1 condition including viral infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J05AC02
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 179.3 Da · C12H21N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL959
Name	Rimantadine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5071
ATC	J05AC02
Molecular formula	C12H21N
Molecular weight	179.3
InChIKey	UBCHPRBFMUDMNC-UHFFFAOYSA-N

SMILES: CC(C12CC3CC(C1)CC(C3)C2)N

IUPAC name: 1-(1-adamantyl)ethanamine

Also known as: Rimantadina, Rimantadine, rimantadin, rimantidin, rimantadine, Rimantadin, SID29215455, Remantidine, RIMANTADINE, SID174006857, RIMANTADINE HYDROCHLORIDE, rac-Rimantadine

Parent form; salt/anhydrous children: CHEMBL535396

Patent coverage: 6,435 distinct patent families (24,811 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Polymerase acidic protein, Solute carrier family 22 member 2, Multidrug and toxin extrusion protein 1, Matrix protein 2, Matrix protein 2.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P06821	7.8	Kd	16	nM	CHEMBL_ACT_3351912
P0DOF8	6.29	Kd	510	nM	CHEMBL_ACT_18704784
P06821	6.29	Kd	510	nM	CHEMBL_ACT_25100646
SLC22A2	5.36	IC50	4400	nM	CHEMBL_ACT_12636198
P0DOF8	5.16	Kd	7000	nM	CHEMBL_ACT_18704821
SLC47A1	5.14	IC50	7300	nM	CHEMBL_ACT_12637859

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	4	MONDO:0005108	EFO:0000763

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01172847	PHASE1	COMPLETED	A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers
NCT01413490	Not specified	COMPLETED	Hepatitis C Rimantadine and Antiviral Combination Therapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).